Get the Stockscreener App
0.595
1.71%
0.01
After Hours:
.60
0.005
+0.84%
Matinas Biopharma Holdings Inc Stock (MTNB) Forecast
The Matinas Biopharma Holdings Inc (MTNB) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.0966, representing a -83.76% decrease from the current price of $0.595. The highest analyst price target is $0.1855, and the lowest is $0.00776.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month MTNB Price Target
Average 0.8155
(+37.05% Upside)
Is Matinas Biopharma Holdings Inc (MTNB) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 55.21 | Neutral |
| STOCH(9,6) | 85.96 | Sell |
| STOCHRSI(14) | 83.73 | Sell |
| MACD(12,26) | 0.00732 | Buy |
| ADX(14) | 24.53 | Neutral |
| William %R | -3.9936 | Sell |
| CCI(14) | 81.80 | Neutral |
Buy: 1
Sell: 3
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.5715
Buy
|
0.5753
Buy
|
| MA20 |
0.5564
Buy
|
0.5663
Buy
|
| MA50 |
0.5646
Buy
|
0.5865
Buy
|
| MA100 |
0.5813
Buy
|
0.7084
Sell
|
| MA200 |
1.1058
Sell
|
0.726
Sell
|
Buy: 7
Sell: 3
Neutral: 0
Summary: Buy
According to our latest analysis, MTNB could be considered a Potential Buy, with 17 technical analysis indicators signaling 8 Buy signals, 6 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on MTNB, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 55.21 indicates that MTNB is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 85.96 indicates that MTNB is oversold. This means that MTNB price is at or near the highest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 83.73 indicates that MTNB is oversold. This suggests that MTNB price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 24.53 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 81.8 indicates that MTNB is still overbought but not to an extreme extent.
Long-term MTNB price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Matinas Biopharma Holdings Inc financial reports and earnings history, Matinas Biopharma Holdings Inc (MTNB) stock could reach $0.7074 by 2030, $0.4119 by 2040 and $1.603 by 2050. See the projected annual prices until 2050 of the Matinas Biopharma Holdings Inc stock below:
- Matinas Biopharma Holdings Inc (MTNB) is expected to reach an average price of $0.2157 in 2035, with a high prediction of $0.2169 and a low estimate of $0.2183. This indicates an $-63.74% rise from the last recorded price of $0.595.
- Matinas Biopharma Holdings Inc (MTNB) stock is projected to chart a bullish course in 2040, with an average price target of $0.2993, representing an $-49.69% surge from its current level. The forecast ranges from a conservative $0.3103 to a sky-high $0.4119.
- Our analysts predict Matinas Biopharma Holdings Inc (MTNB) to jump 33.40% by 2045, soaring from $0.8176 to an average price of $0.7937, potentially reaching $0.773. While $0.8176 is the low estimate, the potential upside is significant.
- Matinas Biopharma Holdings Inc (MTNB) stock is expected to climb by 2050, reaching an average of $1.5003, a $152.15% jump from its current level. However, a wide range of estimates exists, with high and low targets of $1.603 and $1.6529, respectively, highlighting the market's uncertainty.
Matinas Biopharma Holdings Inc Stock (MTNB) Year by Year Forecast
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2025
Matinas Biopharma Holdings Inc Stock (MTNB) is expected to reach an average price of $0.8834 in 2025, with a high prediction of $1.7591 and a low estimate of $0.00776. This indicates an +48.48% rise from the last recorded price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $0.0527 | $0.00776 | $0.1855 | -91.15% |
| June, 2025 | $0.0699 | $0.0118 | $0.1268 | -88.24% |
| July, 2025 | $0.1486 | $0.0991 | $0.3091 | -75.02% |
| August, 2025 | $0.0473 | $0.0173 | $0.2216 | -92.05% |
| September, 2025 | $0.2354 | $0.0196 | $0.4118 | -60.44% |
| October, 2025 | $0.0896 | $0.0387 | $0.3367 | -84.93% |
| November, 2025 | $0.1353 | $0.021 | $0.1973 | -77.26% |
| December, 2025 | $0.1882 | $0.1191 | $0.3006 | -68.37% |
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2026
The predicted value for Matinas Biopharma Holdings Inc (MTNB) in 2026 is set at an average of $0.8691. Estimates vary from a peak of $1.6232 to a trough of $0.115, indicating an +46.07% surge from the present price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.4373 | $0.115 | $0.4573 | -26.51% |
| February, 2026 | $0.4264 | $0.3419 | $0.6441 | -28.34% |
| March, 2026 | $1.0304 | $0.2529 | $1.6232 | +73.18% |
| April, 2026 | $0.8179 | $0.2724 | $1.14 | +37.46% |
| May, 2026 | $0.5559 | $0.4214 | $0.8491 | -6.57% |
| June, 2026 | $0.445 | $0.435 | $0.6082 | -25.21% |
| July, 2026 | $0.2113 | $0.167 | $0.4473 | -64.48% |
| August, 2026 | $0.3292 | $0.2026 | $0.3356 | -44.67% |
| September, 2026 | $0.2338 | $0.1969 | $0.4026 | -60.71% |
| October, 2026 | $0.2494 | $0.1411 | $0.2584 | -58.09% |
| November, 2026 | $0.286 | $0.1504 | $0.335 | -51.94% |
| December, 2026 | $0.7863 | $0.2596 | $1.1063 | +32.16% |
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Matinas Biopharma Holdings Inc (MTNB) is $0.4193, with a high forecast of $0.7886 and a low forecast of $0.0499. This indicates an -29.53% decrease from the last price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.6254 | $0.5309 | $0.7886 | +5.11% |
| February, 2027 | $0.5645 | $0.4422 | $0.7745 | -5.13% |
| March, 2027 | $0.5559 | $0.389 | $0.6836 | -6.58% |
| April, 2027 | $0.41 | $0.385 | $0.6081 | -31.10% |
| May, 2027 | $0.254 | $0.1596 | $0.4537 | -57.30% |
| June, 2027 | $0.1379 | $0.0839 | $0.2943 | -76.82% |
| July, 2027 | $0.3689 | $0.0499 | $0.4722 | -38.00% |
| August, 2027 | $0.4336 | $0.327 | $0.5713 | -27.13% |
| September, 2027 | $0.3349 | $0.182 | $0.4358 | -43.71% |
| October, 2027 | $0.3321 | $0.2295 | $0.4738 | -44.18% |
| November, 2027 | $0.4479 | $0.3263 | $0.5031 | -24.72% |
| December, 2027 | $0.4568 | $0.3645 | $0.5499 | -23.23% |
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2028
In 2028, Matinas Biopharma Holdings Inc (MTNB) is projected to reach an average price of $0.3035, with a high projection of $0.5317 and a low estimate of $0.0753. This indicates an -48.99% fall from the last price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.3666 | $0.3213 | $0.4567 | -38.39% |
| February, 2028 | $0.2686 | $0.2351 | $0.4081 | -54.85% |
| March, 2028 | $0.424 | $0.2649 | $0.5317 | -28.74% |
| April, 2028 | $0.3431 | $0.3005 | $0.4635 | -42.34% |
| May, 2028 | $0.1835 | $0.0978 | $0.3654 | -69.17% |
| June, 2028 | $0.2555 | $0.1207 | $0.2735 | -57.05% |
| July, 2028 | $0.1994 | $0.1836 | $0.2958 | -66.48% |
| August, 2028 | $0.1509 | $0.1455 | $0.2072 | -74.64% |
| September, 2028 | $0.1752 | $0.0853 | $0.2008 | -70.56% |
| October, 2028 | $0.3199 | $0.1153 | $0.4576 | -46.24% |
| November, 2028 | $0.122 | $0.1002 | $0.4044 | -79.49% |
| December, 2028 | $0.0926 | $0.0753 | $0.1503 | -84.44% |
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2029
The 2029 price forecast for Matinas Biopharma Holdings Inc Stock (MTNB) is $0.3306 on average, with a high prediction of $0.6612 and a low estimate of $0.000051. This represents an -44.43% decrease from the previous price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.094 | $0.0646 | $0.1617 | -84.21% |
| February, 2029 | $0.0485 | $0.0754 | $0.1252 | -91.84% |
| March, 2029 | $0.1078 | $0.071 | $0.0727 | -81.89% |
| April, 2029 | $0.0176 | $0.1038 | $0.6612 | -97.05% |
| May, 2029 | $0.00421 | $0.0165 | $0.1026 | -99.29% |
| June, 2029 | $0.00168 | $0.00432 | $0.0291 | -99.72% |
| July, 2029 | $0.017 | $0.000051 | $0.0598 | -97.15% |
| August, 2029 | $0.0121 | $0.00203 | $0.041 | -97.96% |
| September, 2029 | $0.0606 | $0.0144 | $0.0881 | -89.81% |
| October, 2029 | $0.1106 | $0.0529 | $0.2626 | -81.42% |
| November, 2029 | $0.0294 | $0.022 | $0.2069 | -95.07% |
| December, 2029 | $0.6346 | $0.0187 | $0.5244 | +6.66% |
Matinas Biopharma Holdings Inc Stock (MTNB) Price Forecast for 2030
Matinas Biopharma Holdings Inc Stock (MTNB) is expected to reach an average price of $0.5151 in 2030, with a high forecast of $1.0283 and a low forecast of $0.0019. This signifies an -13.43% decrease from the last price of $0.595.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $0.7919 | $0.6753 | $0.7074 | +33.09% |
| February, 2030 | $0.7214 | $0.7529 | $0.7282 | +21.24% |
| March, 2030 | $0.8153 | $0.852 | $0.78 | +37.03% |
| April, 2030 | $0.856 | $0.8708 | $0.8327 | +43.86% |
| May, 2030 | $0.9016 | $0.8897 | $0.8844 | +51.54% |
| June, 2030 | $0.6713 | $0.819 | $0.832 | +12.82% |
| July, 2030 | $0.3135 | $0.3935 | $0.5672 | -47.30% |
| August, 2030 | $0.2346 | $0.0101 | $0.6954 | -60.57% |
| September, 2030 | $0.00781 | $0.00281 | $1.0283 | -98.69% |
| October, 2030 | $0.1445 | $0.0019 | $0.2219 | -75.72% |
| November, 2030 | $0.7161 | $0.2499 | $0.4063 | +20.35% |
| December, 2030 | $0.8671 | $0.8318 | $0.7981 | +45.73% |
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):